Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CMPS 
Compass Pathways Plc (CMPS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CMPS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $15.9
1 Year Target Price $15.9
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -68.64% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 261.97M USD | Price to earnings Ratio - | 1Y Target Price 15.9 |
Price to earnings Ratio - | 1Y Target Price 15.9 | ||
Volume (30-day avg) 11 | Beta 2.25 | 52 Weeks Range 2.25 - 8.54 | Updated Date 06/30/2025 |
52 Weeks Range 2.25 - 8.54 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.4% | Return on Equity (TTM) -60.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 32024673 | Price to Sales(TTM) - |
Enterprise Value 32024673 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.51 | Shares Outstanding 93561800 | Shares Floating 65851569 |
Shares Outstanding 93561800 | Shares Floating 65851569 | ||
Percent Insiders 13.64 | Percent Institutions 56.03 |
Analyst Ratings
Rating 4 | Target Price 15.9 | Buy 4 | Strong Buy 7 |
Buy 4 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Compass Pathways Plc
Company Overview
History and Background
Compass Pathways Plc was founded in 2016. It is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company focuses on developing psilocybin therapy for treatment-resistant depression (TRD) and other mental health disorders.
Core Business Areas
- Drug Development: Focused on the clinical development of COMP360, a proprietary formulation of psilocybin, for various mental health conditions.
- Digital Therapeutics: Exploring digital tools to support patients and therapists in conjunction with COMP360.
- Therapist Training: Developing and providing training programs for therapists to deliver psilocybin therapy effectively.
Leadership and Structure
The company is led by Kabir Nath (CEO). The organizational structure includes departments for research and development, clinical operations, regulatory affairs, and commercial strategy. The board includes investors and experienced pharmaceutical executives.
Top Products and Market Share
Key Offerings
- COMP360 Psilocybin Therapy: COMP360 is Compass Pathways' proprietary formulation of psilocybin for treatment-resistant depression (TRD). It is currently in Phase III clinical trials. Market share is currently 0 as the product is not yet approved. Competitors include other companies developing psychedelic-assisted therapies, such as MindMed (MNMD) and Atai Life Sciences (ATAI).
Market Dynamics
Industry Overview
The mental health treatment industry is large and growing, with unmet needs in areas like treatment-resistant depression. There is increasing interest and investment in psychedelic-assisted therapies as potential breakthrough treatments.
Positioning
Compass Pathways is a leading company in the development of psilocybin therapy for mental health disorders. They have a first-mover advantage in the TRD space.
Total Addressable Market (TAM)
The TAM for mental health treatments is estimated to be in the hundreds of billions of dollars. Compass Pathways is positioned to capture a significant share of the TRD market, estimated to be several billion dollars, if COMP360 is approved.
Upturn SWOT Analysis
Strengths
- First-mover advantage in psilocybin therapy for TRD
- Strong intellectual property position
- Experienced management team
- Advanced clinical trial progress (Phase III)
- Focus on therapist training and standardization of therapy protocols
Weaknesses
- Regulatory uncertainty surrounding psilocybin
- High cash burn rate
- Reliance on a single product (COMP360)
- Potential for adverse effects with psilocybin
- Limited commercialization experience
Opportunities
- Expansion into other mental health indications
- Partnerships with pharmaceutical companies or healthcare providers
- Regulatory approval and market access for COMP360
- Growing awareness and acceptance of psychedelic therapies
- Development of digital therapeutics to enhance therapy effectiveness
Threats
- Competition from other companies developing psychedelic therapies
- Unfavorable regulatory changes
- Clinical trial failures
- Negative public perception of psychedelics
- Difficulty securing reimbursement from payers
Competitors and Market Share
Key Competitors
- MNMD
- ATAI
- GHRS
Competitive Landscape
Compass Pathways has a first-mover advantage and a strong IP position, but faces competition from other companies developing psychedelic therapies. Their focus on therapist training and standardized protocols is a differentiator.
Growth Trajectory and Initiatives
Historical Growth: The company has not yet generated revenue. Growth is measured by progress in clinical trials and partnerships.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of COMP360. Analyst estimates vary widely depending on the likelihood of approval.
Recent Initiatives: Recent initiatives include completing Phase IIb clinical trials, expanding therapist training programs, and engaging with regulatory agencies.
Summary
Compass Pathways is a pioneering company in the field of psychedelic-assisted therapy, particularly with its COMP360 program for treatment-resistant depression. While the company holds a first-mover advantage and strong intellectual property, it faces significant regulatory hurdles and competition. Its success hinges on positive clinical trial outcomes and the ultimate approval of COMP360, which will dictate its growth trajectory and market leadership. Compass Pathways's high cash burn rate and reliance on a single product also need monitoring.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports and filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be complete or accurate. Investment decisions should be made based on individual circumstances and after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Pathways Plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-18 | CEO & Director Mr. Kabir Kumar Nath M.A., M.B.A. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 166 | Website https://compasspathways.com |
Full time employees 166 | Website https://compasspathways.com | ||
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.